Press Releases

Active Biotech AB Year-end report January - December 2012
February 14, 2013 08:30 (CET)
Results from Active Biotech's Phase II/III ANYARA trial for the treatment of renal cell cancer
January 28, 2013 08:30 (CET)
Active Biotech to Present at the JP Morgan 31st Annual Healthcare Conference
January 3, 2013 10:00 (CET)
Laquinimod highlights from Teva Investor Day December 11
December 12, 2012 08:30 (CET)
Teva Investor Meeting December 11
December 11, 2012 08:30 (CET)
Active Biotech and Ipsen announce completion of recruitment of tasquinimod clinical phase III study in prostate cancer
December 10, 2012 07:30 (CET)
Active Biotech's election committee appointed
November 15, 2012 08:30 (CET)
Active Biotech AB Interim report January - September 2012
November 9, 2012 08:30 (CET)
PHASE IIa LAQUINIMOD TRIAL RESULTS SHOW POSITIVE DATA FOR POTENTIAL USE IN ACTIVE CROHN'S DISEASE
October 22, 2012 15:00 (CEST)
Active Biotech's partner Ipsen initiates a proof-of-concept study with tasquinimod in additional cancer indications
October 19, 2012 07:15 (CEST)